Memorial Sloan Kettering doctors are constantly working to improve treatment for people with melanoma through clinical trials. Participating in a clinical trial may give you access to promising melanoma treatments years before they’re available elsewhere. These studies may offer additional options if the cancer has returned after standard treatment.
Through research conducted at MSK, we’ve made enormous strides in improving the treatment options available to people worldwide. Our melanoma clinical trials have resulted in dramatic improvements in survival and quality of life for people with melanoma. Many of the effective melanoma treatments developed over the past decade were studied and tested by members of our melanoma clinical trials team. This includes the immunotherapy drugs ipilimumab (Yervoy®), nivolumab (Opdivo®), and pembrolizumab (Keytruda®), as well as the targeted therapy vemurafenib (Zelboraf®).
Our experts can help determine which clinical trial is right for you, including some of our newly opened clinical trials:
- 23-087 A Phase 2/3 Study of Tebentafusp Alone or With Pembrolizumab Immunotherapy Versus Standard Treatment in People With Previously Treated Melanoma
- 22-285 A Phase I/II Study of DYP688 for People with Advanced Uveal Melanoma and Other Melanomas with GNAQ/11 Gene Mutations
- 22-202 A Phase II Study of Nivolumab Immunotherapy Alone and with Cabozantinib to Prevent Mucosal Melanoma Relapse after Surgery
- 22-151 A Phase II Study of Nemvaleukin Alfa in People with Cutaneous Melanoma or Mucosal Melanoma
- 22-017 A Phase II Study of Axitinib/Nivolumab Alone and with Ipilimumab or Radiation Therapy to Treat Previously Untreated Advanced Mucosal Melanoma
- 23-061 A Phase 2 Study of OKI-179 Plus Binimetinib in People With Melanoma Containing an NRAS Gene Mutation
- 23-098 A Phase 2 Study of IO102/IO103, Nivolumab, and Relatlimab Immunotherapy in People With Melanoma
- 22-132 A Phase I/IIA Study of LNS8801 with and without Pembrolizumab Immunotherapy in People with Advanced Melanoma
MSK is also exploring tumor-infiltrating lymphocyte (TIL) therapy for people with melanoma. TIL therapy is a type of immunotherapy that uses a patient’s immune cells to kill cancer. When we give TIL therapy, we remove the patient’s immune cells from their tumor after surgery and give the cells a treatment that makes them multiply. We then put the cells back into the body to find and attack cancer cells.
Our doctors can help you decide if one of our clinical trials of TIL therapy is right for you:
- 22-322 A Pilot Study of Lifileucel in People with Metastatic Melanoma to the Brain that Is Not Causing Symptoms
- 22-230 A Phase I/II Study of IOV-4001 in People with Inoperable or Metastatic Melanoma or Non-Small Cell Lung Cancer
- 22-198 Expanded Access to Lifileucel to Treat Inoperable or Metastatic Melanoma
- 22-109 A Pilot Study of LN-144 Immunotherapy in People with Metastatic Uveal Melanoma
A complete listing of clinical trials that are currently enrolling new patients is available below.
